Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereof
Provided are novel human islet amyloid polypeptide, also known as amylin and IAPP and proIAPP respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for IAPP and/or proIAPP are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for IAPP and/or proIAPP targeted immunotherapy and diagnostics, respectively.
1. A composition comprising a human-derived monoclonal anti-islet amyloid polypeptide (IAPP) recombinant antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof:
(i) is capable of binding human IAPP;
(ii) does not substantially recognize pathological amyloid-β peptide (Aβ 1-42 ) deposits; and
(iii) preferentially recognizes IAPP aggregates comprising IAPP oligomers and/or fibrils over physiological IAPP,
wherein the antibody or antigen-binding fragment thereof comprises in its variable region:
(a) three complementarity determining regions (CDRs) of the variable heavy chain region (CDRs H1-H3) and the three CDRs of the variable light chain region (CDRs L1-L3) having the amino acid sequences of SEQ ID NOs: 74, 92, 110, 83, 101, and 119 of antibody NI-203.26C11 or a variant thereof, wherein one or more of the six CDRs of the variant comprise one or two amino acid substitutions; and/or
(b) a variable heavy chain (V H ) region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 20 and a variable light chain (V L ) region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 22 of antibody NI-203.26C11.
2. The composition of claim 1 , wherein the antibody or antigen-binding fragment thereof specifically binds an IAPP epitope which comprises the amino acid sequence of CNTATCA (SEQ ID NO: 5).
3. The composition of claim 1 , wherein the antibody or antigen-binding fragment thereof is a chimeric rodent-human or a rodentized antibody.
4. The composition of claim 1 , wherein the antibody or antigen-binding fragment thereof competes with an antibody for specific binding to IAPP.
5. The composition of claim 1 , wherein the antigen-binding fragment is selected from the group consisting of a single chain Fv fragment (scFv), an F(ab′) fragment, an F(ab) fragment, and an F(ab′) 2 fragment.
6. The composition of claim 1 , wherein the antibody or antigen-binding fragment thereof:
(i) comprises a detectable label selected from the group consisting of an enzyme, a radioisotope, a fluorophore, and a heavy metal; or
(ii) is attached to a drug.
7. A kit useful in the diagnosis or monitoring the progression of islet amyloidosis, said kit comprising the composition of claim 1 with reagents and/or instructions for use.
8. The composition of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises in its variable region:
(i) the three CDRs H1-H3 and the three CDRs L1-L3 having the amino acid sequences of SEQ ID NOs: 74, 92, 110, 83, 101, and 119 of antibody NI-203.26C11; and/or
(ii) a V H region comprising the amino acid sequence of SEQ ID NO: 20 and a V L region comprising the amino acid sequence of SEQ ID NO: 22 of antibody NI-203.26C11.
9. The composition of claim 1 , wherein the composition is
(i) a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier;
(ii) a vaccine; or
(iii) a diagnostic composition.
10. The composition of claim 9 , wherein the diagnostic composition comprises reagents conventionally used in immune- or nucleic acid-based diagnostic methods.
11. A composition comprising a human-derived monoclonal anti-IAPP recombinant antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises the three CDRs of the heavy chain variable region and the three CDRs of the light chain variable region, wherein:
(a) the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 74 or a variant thereof, wherein the variant comprises one or two amino acid substitutions;
(b) the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 92 or a variant thereof, wherein the variant comprises one or two amino acid substitutions;
(c) the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 110 or a variant thereof, wherein the variant comprises one or two amino acid substitutions;
(d) the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 83 or a variant thereof, wherein the variant comprises one or two amino acid substitutions;
(e) the CDR-L2 comprises the amino acid sequence of SEQ ID NO: 101 or a variant thereof, wherein the variant comprises one or two amino acid substitutions; and
(f) the CDR-L3 comprises the amino acid sequence of SEQ ID NO: 119 or a variant thereof, wherein the variant comprises one or two amino acid substitutions.
12. The composition of claim 11 , wherein the antibody or antigen-binding fragment thereof comprises a V H region comprising an amino acid sequence at least 90% identical to SEQ ID NO: 20 and a V L region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 22 of antibody NI-203.26C11.
13. The composition of claim 11 , wherein the antibody or antigen-binding fragment thereof comprises in its variable region:
(i) the three CDRs H1-H3 and the three CDRs L1-L3 having the amino acid sequences of SEQ ID NOs: 74, 92, 110, 83, 101, and 119 of antibody NI-203.26C11; and/or
(ii) a V H region comprising the amino acid sequence of SEQ ID NO: 20 and a V L region comprising the amino acid sequence of SEQ ID NO: 22 of antibody NI-203.26C11.
14. The composition of claim 11 , wherein the antibody or antigen-binding fragment thereof:
(i) is capable of binding human IAPP;
(ii) does not substantially recognize pathological amyloid-β peptide (Aβ 1-42 ) deposits; and
(iii) preferentially recognizes IAPP aggregates comprising IAPP oligomers and/or fibrils over physiological IAPP.
15. The composition of claim 11 , wherein the antibody or antigen-binding fragment thereof specifically binds an IAPP epitope which comprises the amino acid sequence of CNTATCA (SEQ ID NO: 5).
16. The composition of claim 11 , wherein the antibody or antigen-binding fragment thereof is a chimeric rodent-human or a rodentized antibody.
17. The composition of claim 11 , wherein the antibody or antigen-binding fragment thereof competes with an antibody for specific binding to IAPP.
18. The composition of claim 11 , wherein the antigen-binding fragment is selected from the group consisting of an scFv, an F(ab′) fragment, an F(ab) fragment, and an F(ab′) 2 fragment.
19. The composition of claim 11 , wherein the antibody or antigen-binding fragment thereof:
(i) comprises a detectable label selected from the group consisting of an enzyme, a radioisotope, a fluorophore, and a heavy metal; or
(ii) is attached to a drug.
20. A kit useful in the diagnosis or monitoring the progression of islet amyloidosis, said kit comprising the composition of claim 11 with reagents and/or instructions for use.
21. The composition of claim 11 , wherein the composition is
(i) a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier;
(ii) a vaccine; or
(iii) a diagnostic composition.
22. The composition of claim 21 , wherein the diagnostic composition comprises reagents conventionally used in immune- or nucleic acid-based diagnostic methods.
23. A method of treating diabetes mellitus type 2 (T2D) in a subject in need thereof, the method comprising administering to the subject the composition of claim 9 .
24. A method of treating or preventing islet rejection following clinical pancreatic islet transplantation in a subject in need thereof, the method comprising administering to the subject the composition of claim 9 and an additional agent.
25. A method of treating diabetes mellitus type 2 (T2D) in a subject in need thereof, the method comprising administering to the subject the composition of claim 21 .
26. A method of treating or preventing islet rejection following clinical pancreatic islet transplantation in a subject in need thereof, the method comprising administering to the subject the composition of claim 21 and an additional agent.